What is the half-life of Survodutide?

Survodutide has a half-life of ~5-6 days, which is why it's typically administered Once weekly for optimal therapeutic effect.

How do I reconstitute Survodutide?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Growth Hormone

Phase 3

Survodutide

Also known as: BI 456906, BI456906

Overview

Key Facts

Primary Goal: A dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma

A dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Survodutide leverages glucagon receptor activation to increase energy expenditure while using GLP-1 agonism for appetite suppression, with a particular focus on metabolic-associated steatohepatitis (MASH) and liver health. Half-Life ~5-6 days Typical Dose 0.3–6 mg Frequency Once weekly Cycle Length Ongoing / indefinite under medical supervision

Dosing Information

Half-Life

~5-6 days

Typical Dose

0.3–6 mg

Frequency

Once weekly

Cycle Length

Ongoing / indefinite under medical supervision

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 3

Phase 2 data showed survodutide produced up to 18.7% weight loss at 46 weeks and significant improvements in MASH histological endpoints, including fibrosis. The compound demonstrated 83% relative reduction in liver fat content. Phase 3 trials are ongoing for both obesity and MASH indications. Boehringer Ingelheim positions survodutide as a liver-focused metabolic therapy with strong weight loss as a co-benefit.